KeyCorp reiterated their overweight rating on shares of Icon Plc (NASDAQ:ICLR) in a research report sent to investors on Monday morning, The Fly reports. The brokerage currently has a $125.00 price target on the medical research company’s stock, up from their prior price target of $115.00. KeyCorp also issued estimates for Icon Plc’s Q4 2017 earnings at $1.41 EPS, Q1 2018 earnings at $1.42 EPS, Q2 2018 earnings at $1.47 EPS, Q3 2018 earnings at $1.52 EPS, Q4 2018 earnings at $1.56 EPS, FY2018 earnings at $5.97 EPS and FY2019 earnings at $5.89 EPS. The analysts noted that the move was a valuation call.
Several other research firms have also recently weighed in on ICLR. SunTrust Banks, Inc. upgraded shares of Icon Plc from a hold rating to a buy rating and increased their target price for the company from $93.00 to $126.00 in a research note on Monday, July 31st. Zacks Investment Research upgraded shares of Icon Plc from a hold rating to a buy rating and set a $126.00 price target for the company in a research note on Friday, September 1st. BidaskClub upgraded shares of Icon Plc from a buy rating to a strong-buy rating in a research note on Tuesday, August 22nd. ValuEngine cut shares of Icon Plc from a buy rating to a hold rating in a research note on Monday, October 2nd. Finally, Robert W. Baird reiterated a buy rating and issued a $123.00 target price on shares of Icon Plc in a research note on Thursday, October 12th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $121.00.
Icon Plc (ICLR) traded up $2.22 on Monday, hitting $115.68. The stock had a trading volume of 251,000 shares, compared to its average volume of 366,874. The stock has a market capitalization of $6,270.00, a price-to-earnings ratio of 21.78, a P/E/G ratio of 1.75 and a beta of 0.62. Icon Plc has a one year low of $73.76 and a one year high of $124.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90.
Icon Plc (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.03. Icon Plc had a return on equity of 28.42% and a net margin of 16.37%. The business had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. During the same period last year, the company earned $1.19 earnings per share. Icon Plc’s quarterly revenue was up 4.8% compared to the same quarter last year. equities analysts expect that Icon Plc will post 5.36 earnings per share for the current year.
Several institutional investors have recently modified their holdings of ICLR. IHT Wealth Management LLC raised its stake in shares of Icon Plc by 16.9% during the second quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock valued at $223,000 after acquiring an additional 24 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Icon Plc by 3.0% during the second quarter. IFP Advisors Inc now owns 2,299 shares of the medical research company’s stock valued at $225,000 after acquiring an additional 67 shares during the last quarter. Huntington National Bank raised its stake in shares of Icon Plc by 5.0% during the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 77 shares during the last quarter. Bangor Savings Bank raised its stake in shares of Icon Plc by 1.4% during the second quarter. Bangor Savings Bank now owns 11,539 shares of the medical research company’s stock valued at $1,128,000 after acquiring an additional 161 shares during the last quarter. Finally, Acrospire Investment Management LLC increased its position in shares of Icon Plc by 20.1% during the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after buying an additional 200 shares during the period. 91.59% of the stock is owned by institutional investors.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with our FREE daily email newsletter.